




# REMARKS


Claims 1 to 31 are pending in this application. Applicants are herein amending claim 13 to correct an obvious typographical error. No new matter is introduced by the amendment to the claim. Claims 1 to 31 are subject to restriction under 35 U.S.C. § 121 as follows:

Group	Claims	Subject Matter	Class/Subclass	Election of Single Species Required?
I	1-26, and 31 (in part)	Compounds/compositions of formula I wherein Q is  and X is NR <sup>8</sup>	548 with various subclasses	yes
II	1-26, and 31 (in part)	Compounds/compositions of formula I wherein Q is  and X is O	549 with various subclasses	yes
III	1-26, and 31 (in part)	Compounds/compositions of formula I wherein Q is  and X is S	549 with various subclasses	yes
IV	1-26, and 31 (in part)	Compounds/compositions of formula I not in Groups I-III	544/546/548/549 with various subclasses	yes possibly subject to further restriction
V	27-30	Methods of use ( <i>i.e.</i> , treating depression)	514 with various subclasses	no possibly subject to further restriction

Applicants hereby elect *with traverse* to prosecute subject matter of **Group I**. Applicants traverse the restriction requirement and request reconsideration thereof. It is

applicants' understanding that they will be entitled, as a matter of right, to rejoinder of the method claims of Groups V, which depend from or otherwise include all the limitations of elected Group I. If the compounds of Group I are examined and deemed to be patentable, it follows that any method of treatment employing the same compounds are necessarily novel and unobvious. Accordingly, it would appear that examining all of the claims of Group I and Group V in a single application would not be unduly burdensome.

Applicants hereby elect the following species within Group I for the sole purpose of carrying out the search of the elected claims:




N-[3-(5-fluoro-1*H*-indol-3-yl)cyclopentyl]-N-[(8-methoxy)-  
2,3-dihydro-1,4-benzodioxin-2-yl]methylamine  
(shown in Example 2 with specific stereochemistry)

### Conclusions

Applicants respectfully request reconsideration of the restriction requirement in view of the remarks. If the Examiner has any questions, the Examiner is invited to call the undersigned at (215) 557-3861.

Date: April 29, 2005

  
Wendy A. Choi  
Registration No. 36,697

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439